Responses
Clinical and epidemiological research
Extended report
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.